On January 13, 2022, Green Valley (Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate (marketed as "GV-971"), the company's innovative drug for treating Alzheimer's disease (AD). The letter indicated the "Study May Proceed" with the proposed clinical investigation in the treatment of patients with early-stage Parkinson's disease (PD). The IND effective date is December 16, 2021. - Click here if this is your press release! - eTurboNews | Trends | Travel News
/PRNewswire/ On January 13, 2022, Green Valley (Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on.
Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate's Global Phase II Clinical Trial in Treating Parkinson's Disease - read this article along with other careers information, tips and advice on BioSpace
(1)
TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needs
More than 500,000 individuals worldwide living with multiple sclerosis (MS) have been treated with TECFIDERA, which has a well-established safety and efficacy profile
Biogen s expansion in China now includes treatment options approved for relapsing MS and spinal muscular atrophy
CAMBRIDGE, Mass., April 15, 2021(Nasdaq: BIIB) today announced that China s National Medical Products Administration (NMPA) has approved TECFIDERA (dimethyl fumarate) for the treatment of relapsing multiple sclerosis (MS). First introduced in 2013, TECFIDERA has demonstrated a well-established safety and efficacy profile with more than 10 years of data from clinical trials and real-world experience.